OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study

Trial Profile

OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Sep 2015

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Myocardial infarction
  • Focus Pharmacokinetics
  • Most Recent Events

    • 07 Sep 2015 New trial record
    • 02 Sep 2015 Primary endpoint has been met. (Area under the ticagrelor plasma concentration versus time curve (AUC0-1) over 1 hour post ticagrelor administration), according to an abstract presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
    • 02 Sep 2015 Primary endpoint has been met. (Ticagrelors Cmax over 1 hour post ticagrelor administration), according to an abstract presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top